Drug Profile
Gilteritinib companion diagnostic - Invivoscribe Technologies
Alternative Names: ASP 2215 hemifumarate companion diagnostic - Astellas/Invivoscribe; Gilteritinib fumarate companion diagnostic - Astellas/Invivoscribe; LeukoStrat CDx FLT3 Mutation AssayLatest Information Update: 27 May 2020
Price :
$50
*
At a glance
- Originator Invivoscribe Technologies
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Acute myeloid leukaemia
Most Recent Events
- 12 May 2020 Registered for Acute myeloid leukaemia (Diagnosis) in Australia (unspecified route)
- 12 May 2020 Invivoscribe Technologies submitted LeukoStrat® CDx FLT3 Mutation Assay for approval to regulatory authorities in China
- 29 Nov 2018 Invivoscribe announces intention to launch to gilteritinib companion diagnostic in Japan for Acute myeloid leukemia in 2018